EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Multizentrische StudieVergleichsstudieOpen Access · CC BY 4.0

Safety and Immunogenicity of the Live-Attenuated Quadrivalent Dengue Vaccine V181 Compared With Butantan-DV Among Healthy Adults in Brazil: A Randomized, Double-Blind, Phase 2 Trial

David Alexanderian, Fabiano Ramos, Soumya Chatterjee iD, Alexandre Vargas Schwarzbold iD, Ana Paula Loch, Ariane Cristina Barboza Zanetti, Qiuxu Chen, Jason Martin, Matthew T Onorato iD, Germán Áñez iD, V181-002 Team

Clinical Infectious Diseases · 2026

DOI: 10.1093/cid/ciag349 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Infectious Diseases, 2026. Verfasst von David Alexanderian und 10 weiteren Autor:innen. Beteiligte Einrichtung: MRL, Merck & Co., Inc., Rahway, New Jersey, USA. Hauptthemen laut MEDLINE: Dengue Vaccines, Dengue, Immunogenicity, Vaccine. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Merck Sharp & Dohme LLC, Merck & Co., Inc., Fundação Butantan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Dengue is caused by infection with 1 of 4 dengue virus (DENV) serotypes (DENV-1 to DENV-4). V181 and Butantan-Dengue Vaccine (Butantan-DV) are independently developed, single-dose, quadrivalent dengue vaccines based on the same attenuated parental strains.

Methods

In this randomized, double-blind, active comparator–controlled, multisite, phase 2 trial, we compared the safety and immunogenicity of V181 and Butantan-DV in healthy adults in Brazil. The primary immunogenicity objectives were to compare vaccine-induced neutralizing antibody geometric mean titers (GMTs) and seroconversion rates for DENV-1 to DENV-4 at day 28 postvaccination. The primary and secondary safety objectives, respectively, were to assess vaccine-related serious adverse events and the proportion of participants experiencing solicited adverse events through day 28 postvaccination.

Results

Overall, 1364 participants were assigned (1:1) to receive V181 (n = 682) or Butantan-DV (n = 682). At day 28 postvaccination, V181 induced a noninferior immune response to Butantan-DV for DENV-1 and DENV-2 but not DENV-3 and DENV-4, as measured using GMT ratios. Noninferiority was established for all DENV serotypes based on seroconversion rates. Most participants developed a trivalent or tetravalent neutralizing antibody response. Vaccine viremia was detected for each DENV serotype. V181 and Butantan-DV were generally well tolerated.

Conclusions

V181 was immunogenic in adults, and while immunogenicity was noninferior to Butantan-DV for DENV-1 and DENV-2, seroconversion rates were noninferior for DENV-1 to DENV-4. The safety profile of V181 is comparable to that of Butantan-DV and supports its continued evaluation as a single-dose quadrivalent vaccine for dengue prevention. Clinical Trials Registration NCT05710224

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dengue VaccinesDengueImmunogenicity, VaccineHumansAdultFemaleBrazilDouble-Blind MethodMaleAntibodies, ViralVaccines, AttenuatedAntibodies, NeutralizingYoung AdultDengue VirusAdolescentMiddle AgedHealthy VolunteersSeroconversion

Stichwörter der Autor:innen

DENVV181dengue virusphase 2vaccine

Substanzen

Dengue VaccinesAntibodies, ViralVaccines, AttenuatedAntibodies, Neutralizing

Autor:innen und Institutionen

  • MRL, Merck & Co., Inc., Rahway, New Jersey, USA.
  • Infectious Diseases Service, Hospital São Lucas da PUC do Rio Grande do Sul, Porto Alegre, Brazil.
  • School of Medicine, Department of Health Sciences, Universidade Federal de Santa Maria, Santa Maria, Brazil.
  • Instituto Butantan, São Paulo, Brazil.

ORCID-Profile: Soumya Chatterjee, Alexandre Vargas Schwarzbold, Matthew T Onorato, Germán Áñez

Förderung

  • Merck Sharp & Dohme LLC
  • Merck & Co., Inc.
  • Fundação Butantan
  • Butantan-DV

Zitieren

APA

Alexanderian, D., Ramos, F., Chatterjee, S., Schwarzbold, A. V., Loch, A. P., Zanetti, A. C. B., Chen, Q., Martin, J., Onorato, M. T., Áñez, G., & V181-002 Team (2026). Safety and Immunogenicity of the Live-Attenuated Quadrivalent Dengue Vaccine V181 Compared With Butantan-DV Among Healthy Adults in Brazil: A Randomized, Double-Blind, Phase 2 Trial. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciag349

Vancouver

Alexanderian D, Ramos F, Chatterjee S, Schwarzbold AV, Loch AP, Zanetti ACB, et al. Safety and Immunogenicity of the Live-Attenuated Quadrivalent Dengue Vaccine V181 Compared With Butantan-DV Among Healthy Adults in Brazil: A Randomized, Double-Blind, Phase 2 Trial. Clinical Infectious Diseases. 2026. doi:10.1093/cid/ciag349

BibTeX
@article{Alexanderian2026,
  author = {Alexanderian, David and Ramos, Fabiano and Chatterjee, Soumya and Schwarzbold, Alexandre Vargas and Loch, Ana Paula and Zanetti, Ariane Cristina Barboza and Chen, Qiuxu and Martin, Jason and Onorato, Matthew T and Áñez, Germán and V181-002 Team, V181-002 Team},
  title = {Safety and Immunogenicity of the Live-Attenuated Quadrivalent Dengue Vaccine V181 Compared With Butantan-DV Among Healthy Adults in Brazil: A Randomized, Double-Blind, Phase 2 Trial},
  journal = {Clinical Infectious Diseases},
  year = {2026},
  doi = {10.1093/cid/ciag349}
}
Kostenlos starten →